adv-tk/gcv
Biologicalexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2006 (NCT02202564)
Timeline
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- adv-tk/gcv
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03576612 | Phase 1 | Feb 27, 2018 | Candel Therapeutics, Harvard University, Johns Hopkins University |
| NCT00870181 | Phase 2 | Jan 1, 2008 | Capital Medical University, Huazhong University of Science and Technology |
| NCT02202564 | Phase 2 | Oct 31, 2006 | Capital Medical University, Huazhong University of Science and Technology |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 2 | 0 | 1 | 2006 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 2 | 1 | 2006 |
| Candel Therapeutics | For profit | 1 | 0 | 1 | 2018 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2018 |
5 organizations
Page 1 / 1